留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肾移植排斥反应临床诊疗技术规范(2019版)

中华医学会器官移植学分会

中华医学会器官移植学分会. 肾移植排斥反应临床诊疗技术规范(2019版)[J]. 器官移植, 2019, 10(5): 505-512. doi: 10.3969/j.issn.1674-7445.2019.05.008
引用本文: 中华医学会器官移植学分会. 肾移植排斥反应临床诊疗技术规范(2019版)[J]. 器官移植, 2019, 10(5): 505-512. doi: 10.3969/j.issn.1674-7445.2019.05.008
Branch of Organ Transplantation of Chinese Medical Association. Technical specification for the diagnosis and treatment on rejection of renal transplantation (2019 edition)[J]. ORGAN TRANSPLANTATION, 2019, 10(5): 505-512. doi: 10.3969/j.issn.1674-7445.2019.05.008
Citation: Branch of Organ Transplantation of Chinese Medical Association. Technical specification for the diagnosis and treatment on rejection of renal transplantation (2019 edition)[J]. ORGAN TRANSPLANTATION, 2019, 10(5): 505-512. doi: 10.3969/j.issn.1674-7445.2019.05.008

肾移植排斥反应临床诊疗技术规范(2019版)

doi: 10.3969/j.issn.1674-7445.2019.05.008
基金项目: 

国家自然科学基金 81570680

国家自然科学基金 81571555

详细信息
    通讯作者:

    石炳毅, Email:shibingyi666@126.com; 李宁, Email:sxtylining666@126.com

  • 中图分类号: R617, R392.4, R692.5

Technical specification for the diagnosis and treatment on rejection of renal transplantation (2019 edition)

  • 摘要: 为了进一步规范肾移植排斥反应的临床诊断与治疗, 中华医学会器官移植学分会组织器官移植学专家, 总结各移植中心的肾移植临床经验, 在《中国肾脏移植排斥反应临床诊疗指南(2016版)》的基础上, 并依据Banff标准, 从超急性排斥反应、急性加速性排斥反应、急性排斥反应、慢性排斥反应等方面, 制订本规范。

     

  • [1] NANKIVELL BJ, ALEXANDER SI. Rejection of the kidney allograft[J]. N Engl J Med, 2010, 363(15):1451-1462. DOI: 10.1056/NEJMra0902927.
    [2] BROECKER V, MENGEL M. The significance of histological diagnosis in renal allograft biopsies in 2014[J]. Transpl Int, 2015, 28(2):136-143. DOI: 10.1111/tri.12446.
    [3] JORDAN SC, PESCOVITZ MD. Presensitization: the problem and its management[J]. Clin J Am Soc Nephrol, 2006, 1(3):421-432. doi: 10.2215/CJN.01651105
    [4] STEGALL MD, GLOOR J, WINTERS JL, et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody[J]. Am J Transplant, 2006, 6(2):346-351. doi: 10.1111/j.1600-6143.2005.01178.x
    [5] EL-ZOGHBY ZM, STEGALL MD, LAGER DJ, et al. Identifying specific causes of kidney allograft loss[J]. Am J Transplant, 2009, 9(3):527-535. DOI: 10.1111/j.1600-6143.2008.02519.x.
    [6] SELLARÉS J, DE FREITAS DG, MENGEL M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence[J]. Am J Transplant, 2012, 12(2):388-399. DOI: 10.1111/j.1600-6143.2011.03840.x.
    [7] WIEBE C, GIBSON IW, BLYDT-HANSEN TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant[J]. Am J Transplant, 2012, 12(5):1157-1167. DOI: 10.1111/j.1600-6143.2012.04013.x.
    [8] NANKIVELL BJ. Clinical allograft rejection syndromes in kidney transplantation[M]// KIRK AD, KNECHTLE SJ, LARSEN CP, et al. Textbook of organ transplantation. Hoboken: John Wiley & Sons Ltd, 2014.
    [9] 中华医学会器官移植学分会, 中国医师协会器官移植医师分会.中国肾移植排斥反应临床诊疗指南(2016版)[J].器官移植, 2016, 7(5):332-338. DOI: 10.3969/j.issn.1674-7445.2016.05.002.

    Branch of Organ Transplantation of Chinese Medical Association, Branch of Organ Transplant Physician of Chinese Medical Doctor Association. Guideline on clinical diagnosis and treatment for rejection of renal transplantation in China(2016 edition)[J]. Organ Transplant, 2016, 7(5): 332-338. DOI: 10.3969/j.issn.1674-7445.2016.05.002.
    [10] YAICH S. ABO-incompatible kidney transplantation[J]. Saudi J Kidney Dis Transpl, 2013, 24(3):463-472. doi: 10.4103/1319-2442.111009
    [11] MURAMATSU M, GONZALEZ HD, CACCIOLA R, et al. ABO incompatible renal transplants: good or bad?[J]. World J Transplant, 2014, 4(1):18-29. DOI: 10.5500/wjt.v4.i1.18.
    [12] JALALZADEH M, MOUSAVINASAB N, PEYROVI S, et al. The impact of acute rejection in kidney transplantation on long-term allograft and patient outcome[J]. Nephrourol Mon, 2015, 7(1):e24439. DOI: 10.5812/numonthly.24439.
    [13] RANDHAWA P. T-cell-mediated rejection of the kidney in the era of donor-specific antibodies: diagnostic challenges and clinical significance[J]. Curr Opin Organ Transplant, 2015, 20(3):325-332. DOI: 10.1097/MOT.0000000000000189.
    [14] ZHANG RB. Clinical management of kidney allograft dysfunction[J]. Open J Organ Transpl Surg, 2014, 4(2): 7-14. DOI: 10.4236/ojots.2014.42002.
    [15] GABER AO, FIRST MR, TESI RJ, et al. Results of the double-blind, randomized, multicenter, phase Ⅲ clinical trial of thymoglobulin versus atgam in the treatment of acute graft rejection episodes after renal transplantation[J]. Transplantation, 1998, 66(1):29-37. doi: 10.1097/00007890-199807150-00005
    [16] MCDONALD S, RUSS G, CAMPBELL S, et al. Kidney transplant rejection in Australia and New Zealand: relationships between rejection and graft outcome[J]. Am J Transplant, 2007, 7(5):1201-1208. doi: 10.1111/j.1600-6143.2007.01759.x
    [17] Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients[J]. Am J Transplant, 2009, 9(Suppl 3): S1-S155. DOI: 10.1111/j.1600-6143.2009.02834.x.
    [18] SALVADORI M, BERTONI E. Acute antibody-mediated rejection in kidney transplantation: clinical and therapeutic aspects[J]. J Nephrol Ther, 2013, 4(1):146. DOI: 10.4172/2161-0959.1000146.
    [19] FARKASH EA, COLVIN RB. Diagnostic challenges in chronic antibody-mediated rejection[J]. Nat Rev Nephrol, 2012, 8(5):255-257. DOI: 10.1038/nrneph.2012.61.
    [20] SIS B, HALLORAN PF. Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibody-mediated rejection[J]. Curr Opin Organ Transplant, 2010, 15(1):42-48. DOI: 10.1097/MOT.0b013e3283352a50.
    [21] HIDALGO LG, SIS B, SELLARES J, et al. NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection[J]. Am J Transplant, 2010, 10(8):1812-1822. DOI: 10.1111/j.1600-6143.2010.03201.x.
    [22] SIS B, MENGEL M, HAAS M, et al. Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups[J]. Am J Transplant, 2010, 10(3):464-471. DOI: 10.1111/j.1600-6143.2009.02987.x.
    [23] COLVIN RB. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis[J]. J Am Soc Nephrol, 2007, 18(4):1046-1056. doi: 10.1681/ASN.2007010073
    [24] ALLEN U, HUMAR A, LIMAYE A, et al. Discipline of transplant infectious diseases (ID). foreword[J]. Am J Transplant, 2009, 9(Suppl 4): S1-S2. DOI: 10.1111/j.1600-6143.2009.02886.x.
    [25] TERASAKI PI, OZAWA M. Predicting kidney graft failure by HLA antibodies: a prospective trial[J]. Am J Transplant, 2004, 4(3):438-443. doi: 10.1111/j.1600-6143.2004.00360.x
    [26] DJAMALI A, KAUFMAN DB, ELLIS TM, et al. Diagnosis and management of antibody-mediated rejection: current status and novel approaches[J]. Am J Transplant, 2014, 14(2): 255-271. DOI: 10.1111/ajt.12589.
    [27] VALENZUELA NM, REED EF. Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies[J]. J Clin Invest, 2017, 127(7): 2492-2504. DOI: 10.1172/JCI90597.
    [28] HARIRIAN A. Current status of the evaluation and management of antibody-mediated rejection in kidney transplantation[J]. Curr Opin Nephrol Hypertens, 2015, 24(6): 576-581. DOI: 10.1097/MNH.0000000000000167.
    [29] MORATH C, ZEIER M. Transplantation: molecular diagnosis of kidney transplant rejection[J]. Nat Rev Nephrol, 2014, 10(8): 429-430. DOI: 10.1038/nrneph.2014.106.
    [30] WILFLINGSEDER J, REINDL-SCHWAIGHOFER R, SUNZENAUER J, et al. MicroRNAs in kidney transplantation[J]. Nephrol Dial Transplant, 2015, 30(6):910-917. DOI: 10.1093/ndt/gfu280.
    [31] LUCAS JG, CO JP, NWAOGWUGWU UT, et al. Antibody-mediated rejection in kidney transplantation: an update[J]. Expert Opin Pharmacother, 2011, 12(4):579-592. DOI: 10.1517/14656566.2011.525219.
    [32] SINGH N, PIRSCH J, SAMANIEGO M. Antibody-mediated rejection: treatment alternatives and outcomes[J]. Transplant Rev (Orlando), 2009, 23(1):34-46. DOI: 10.1016/j.trre.2008.08.004.
    [33] PUTTARAJAPPA C, SHAPIRO R, TAN HP. Antibody-mediated rejection in kidney transplantation: a review[J]. J Transplant, 2012:193724. DOI: 10.1155/2012/193724.
    [34] KIM M, MARTIN ST, TOWNSEND KR, et al. Antibody-mediated rejection in kidney transplantation: a review of pathophysiology, diagnosis, and treatment options[J]. Pharmacotherapy, 2014, 34(7):733-744. DOI: 10.1002/phar.1426.
    [35] NANKIVELL BJ, BORROWS RJ, FUNG CL, et al. The natural history of chronic allograft nephropathy[J]. N Engl J Med, 2003, 349(24):2326-2333. doi: 10.1056/NEJMoa020009
    [36] HEEMANN U, LUTZ J. Pathophysiology and treatment options of chronic renal allograft damage[J]. Nephrol Dial Transplant, 2013, 28(10):2438-2446. DOI: 10.1093/ndt/gft087.
    [37] BHATTI AB, USMAN M. Chronic renal transplant rejection and possible anti-proliferative drug targets[J]. Cureus, 2015, 7(11): e376. DOI: 10.7759/cureus.376.
    [38] TANABE K, INUI M. Desensitization for prevention of chronic antibody-mediated rejection after kidney transplantation[J]. Clin Transplant, 2013, 27(Suppl 26):2-8. DOI: 10.1111/ctr.12260.
    [39] TAIT BD, SÜSAL C, GEBEL HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation[J]. Transplantation, 2013, 95(1):19-47. DOI: 10.1097/TP.0b013e31827a19cc.
  • 加载中
计量
  • 文章访问数:  69
  • HTML全文浏览量:  11
  • PDF下载量:  36
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-06-28
  • 网络出版日期:  2021-01-19
  • 刊出日期:  2019-09-15

目录

    /

    返回文章
    返回